Savara (SVRA)

• Market cap: $1.09B
• 1 day: 3.52%
• 5 days: 2.71%
• 1 month: -5.36%
• 3 months: -1.12%
• 6 months: 28.33%
• Year to date: -6.03%
• 1 year: 61.59%
• 5 years: 211.76%
• 10 years: -77.05%
• Sector: Healthcare
• Industry: Biotechnology

About: Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).

Employees: 70